Logo

skin cancer

Castle Biosciences Growing Data for Skin Cancer Tests as Adoption Drives Q1 Revenue Growth
Premium

The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.

DermTech Stock Soars on News of Additional Coverage for Melanoma Detection Test

The molecular diagnostics firm said two payors with 1.2 million members in New York and Hawaii will cover DermTech's noninvasive testing platform.

Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy

The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug. 

SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay

The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.

Castle Bio Q2 Growth Driven by Skin Cancer Testing as New Acquisitions Boost Sales
Premium

The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories. 

May 26, 2022

Local Coverage Determinations Roundup: Castle Bio, SkylineDx

May 9, 2022

Castle Biosciences Q1 Revenues Grow 18 Percent

May 4, 2022

DermTech Posts 48 Percent Jump in Q1 Revenues

Apr 29, 2022

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

Mar 2, 2022

DermTech Q4 Revenues Jump 52 Percent, Miss Wall Street Estimate

Feb 28, 2022

Castle Biosciences Q4 Revenues Grow 45 Percent

Nov 16, 2021

Cancer Genomic Analysis Reveals Distinct Features in Tumors From Patients Under 50 Years Old

Nov 9, 2021

Dermtech Q3 Revenues Rise 122 Percent

Nov 8, 2021

Castle Biosciences Q3 Revenues Rise 54 Percent

Oct 27, 2021

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

Sep 16, 2021

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Aug 24, 2021

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

Aug 9, 2021

Castle Biosciences Q2 Revenues Rise 79 Percent

Jun 9, 2021

Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic

May 11, 2021

Castle Biosciences to Expand Range of Dermatology Diagnostics Beyond Cancer
Premium

May 10, 2021

Castle Biosciences Q1 Revenues Up 31 Percent

Mar 11, 2021

Eye Color GWAS Leads to 50 New Loci, Underscoring Trait's Complexity

Mar 8, 2021

Castle Biosciences Q4 Revenues Down 2 Percent

Mar 5, 2021

DermTech Q4 Revenues Up 31 Percent

Feb 16, 2021

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.